AVBP vs LXRX: stock comparison and AI forecast
Arrivent Biopharma, Inc. (AVBP) and Lexicon Pharmaceuticals, Inc. (LXRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AVBP Arrivent Biopharma, Inc.
- Price
- $13.02 -56.4% · 6M
- Market Cap
- $642M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
LXRX Lexicon Pharmaceuticals, Inc.
- Price
- $1.44 -10.0% · 6M
- Market Cap
- $650M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- AVBP and LXRX have similar market capitalizations ($642M and $650M).
- Over the last six months LXRX returned -10.0% and AVBP -56.4%.
- LXRX carries 0.43 times debt per unit of equity, against 0.08 times for AVBP.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AVBP | LXRX |
|---|---|---|
| Market Cap | $642M | $650M |
| P/B Ratio | 1.75x | 3.72x |
| EPS | $-2.57 | $-0.22 |
| Book Value/Share | $7.44 | $0.39 |
| Revenue/Share | – | $0.09 |
Profitability & Margins
| Metric | AVBP | LXRX |
|---|---|---|
| ROE | -44.6% | -35.0% |
| ROA | -41.5% | -24.4% |
| ROIC | -48.0% | -23.2% |
| Operating Margin | – | -131.4% |
| Net Margin | – | -147.4% |
| EBT Margin | – | -129.0% |
Financial Health
| Metric | AVBP | LXRX |
|---|---|---|
| Current Ratio | 14.16x | 13.37x |
| Quick Ratio | – | 13.29x |
| D/E Ratio | 0.08x | 0.43x |
| Financial Leverage | 1.08x | 1.43x |
| Interest Coverage | – | -23.5x |
| Working Capital | $366M | $182M |
Cash Flow
| Metric | AVBP | LXRX |
|---|---|---|
| Operating Cash Flow | -$148M | -$65M |
Operational Efficiency
| Metric | AVBP | LXRX |
|---|---|---|
| Asset Turnover | – | 0.17x |
| Receivables Turnover | – | 25.2x |
| Inventory Turnover | – | 0.3x |
| Fixed Assets Turnover | – | 25.1x |
| Days Sales Outstanding | – | 14 days |
| Days Inventory | – | 1219 days |
| Payables Period | – | 2389 days |
| Cash Conversion Cycle | – | -1155 days |
Income Statement
| Metric | AVBP | LXRX |
|---|---|---|
| Total Revenue | – | $41M |
| Operating Income | -$176M | -$54M |
| Net Income | -$164M | -$61M |
| R&D Expense | $144M | $60M |
| SG&A Expense | – | $35M |
| Cost of Goods Sold | – | $360K |
Dividend & Shareholder Information
| Metric | AVBP | LXRX |
|---|---|---|
| Shares Outstanding | 49M | 445M |
AVBP vs LXRX: stock comparison and AI forecast
Which is bigger, AVBP or LXRX?
AVBP and LXRX have similar market capitalizations ($642M and $650M).
Which stock performed better over the last six months, AVBP or LXRX?
Over the last six months LXRX returned -10.0% and AVBP -56.4%.
Which one does Intratio's AI model rank higher, AVBP or LXRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.